TransMedics Group (TMDX)
(Delayed Data from NSDQ)
$145.99 USD
-3.20 (-2.14%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $145.56 -0.43 (-0.29%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$145.99 USD
-3.20 (-2.14%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $145.56 -0.43 (-0.29%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth B Momentum D VGM
Zacks News
TransMedics (TMDX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
TransMedics (TMDX) delivered earnings and revenue surprises of 68% and 19.72%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Tandem Diabetes Care, Inc. (TNDM) Q1 Earnings Expected to Decline
by Zacks Equity Research
Tandem Diabetes Care, Inc. (TNDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TransMedics (TMDX) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
TransMedics (TMDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in TransMedics (TMDX): Can Its 12.3% Jump Turn into More Strength?
by Zacks Equity Research
TransMedics (TMDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
TransMedics (TMDX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
TransMedics (TMDX) delivered earnings and revenue surprises of 25% and 28.76%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
5 Winning Medical Product Stocks That Still Have Room to Run
by Indrajit Bandyopadhyay
Despite ongoing macro challenges, medical product stocks like Cardinal Health (CAH), TransMedics Group (TMDX), Olink Holding (OLK), Silk Road Medical (SILK) and Neuronetics (STIM) are likely to gain from strong fundamentals.
3 Medical Stocks Creating Wealth Despite Macro Challenges
by Indrajit Bandyopadhyay
Here we discuss three stocks - CAH, LNTH and TMDX - that have been creating wealth for their investors in 2022 as several competitors faltered amid macro challenges. Will the trend continue?
Is Esperion Therapeutics (ESPR) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Esperion Therapeutics (ESPR) and TransMedics (TMDX) have performed compared to their sector so far this year.
TransMedics (TMDX) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does TransMedics (TMDX) have what it takes to be a top stock pick for momentum investors? Let's find out.
TransMedics (TMDX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
TransMedics (TMDX) delivered earnings and revenue surprises of 37.50% and 35.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Teleflex (TFX) Surpasses Q3 Earnings Estimates
by Zacks Equity Research
Teleflex (TFX) delivered earnings and revenue surprises of 5.48% and 0.65%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights TransMedics, PROCEPT BioRobotics and Sensus Healthcare
by Zacks Equity Research
TransMedics, PROCEPT BioRobotics and Sensus Healthcare are part of the Zacks top Analyst Blog Highlights.
3 Resilient Medical Stocks to Watch as Rate Hikes Continue
by Indrajit Bandyopadhyay
Here we discuss three Medical-Instruments stocks - TMDX, PRCT & SRTS - that continued to grow in the first nine months of 2022 even though three Fed rate hikes dragged broader indices down.
TransMedics (TMDX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
TransMedics (TMDX) delivered earnings and revenue surprises of -28.13% and 26.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
TransMedics (TMDX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
TransMedics (TMDX) delivered earnings and revenue surprises of -8.57% and 55.34%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
TransMedics (TMDX) Soars 9.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
TransMedics (TMDX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
TransMedics (TMDX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
TransMedics (TMDX) delivered earnings and revenue surprises of -6.98% and 26.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Pacific Biosciences of California (PACB) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pacific Biosciences (PACB) delivered earnings and revenue surprises of -7.14% and 0.05%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
TransMedics (TMDX) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
TransMedics (TMDX) delivered earnings and revenue surprises of -46.88% and -30.50%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
Cardinal Health (CAH) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Cardinal Health's (CAH) fiscal first-quarter results are likely to reflect solid performance in the Pharmaceutical segment.
TransMedics (TMDX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
TransMedics (TMDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
TransMedics (TMDX) Receives FDA Nod for OCS Heart System
by Zacks Equity Research
TransMedics' (TMDX) OCS Heart System is expected to enable broader use of donor hearts for transplantation in the United States.
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE